Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer

Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X, about a recent paper by Alexios Matikas et al., commenting:

“Dose-Dense vs Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: Final Results of the PANTHER Trial
mFU: 10.3years
Dose-dense adjuvant regimen is statistically associated with better RFS, EFS, and DDFS. OS is not significant (HR:0.82).”

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial

Journal: Journal of Clinical Oncology

Author: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G. Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis and Jonas Bergh

Source: Yakup Ergün/X